Therapies for Long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study).
Therapies for Long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study).
复制标题
DOI：
10.1136/bmjopen-2021-060413
复制
发表时间：
2022-04-26
期刊：
影响因子：
2.9
通讯作者：
Calvert, Melanie
中科院分区：
文献类型：
--
作者：
Haroon, Shamil;Nirantharakumar, Krishnarajah;Hughes, Sarah E.;Subramanian, Anuradhaa;Aiyegbusi, Olalekan Lee;Davies, Elin Haf;Myles, Puja;Williams, Tim;Turner, Grace;Chandan, Joht Singh;McMullan, Christel;Lord, Janet;Wraith, David C.;McGee, Kirsty;Denniston, Alastair K.;Taverner, Thomas;Jackson, Louise J.;Sapey, Elizabeth;Gkoutos, George;Gokhale, Krishna;Leggett, Edward;Iles, Clare;Frost, Christopher;McNamara, Gary;Bamford, Amy;Marshall, Tom;Zemedikun, Dawit T.;Price, Gary;Marwaha, Steven;Simms-Williams, Nikita;Brown, Kirsty;Walker, Anita;Jones, Karen;Matthews, Karen;Camaradou, Jennifer;Saint-Cricq, Michael;Kumar, Sumita;Alder, Yvonne;Stanton, David E.;Agyen, Lisa;Baber, Megan;Blaize, Hannah;Calvert, Melanie
COVID-19患者经常出现症状，生活质量受损超过4-12周，通常称为长期COVID。长期COVID是一种还是几种不同的综合征尚不清楚。需要为适当的治疗建立证据基础。我们的目的是评估长期COVID综合征在非住院患者中的症状负担和潜在病理生理学，并评估潜在的治疗方法。将从临床实践研究数据链的匿名初级保健记录中选择4000名既往COVID-19诊断的非住院患者和1000名匹配对照组，并由他们的全科医生邀请他们参与数字平台（Atom 5）。个人将报告症状，生活质量，工作能力和患者报告的结果措施。将每月收集数据，持续1年。统计聚类方法将用于识别不同的长COVID-19症状群。将邀请来自四个最流行的集群和两个对照组的个体参加BioWear子研究，该子研究将通过测量免疫学参数和活动记录仪进一步表型长COVID症状集群。我们将审查有关病毒感染后综合征和新型冠状病毒病干预措施的现有证据，以绘制每种新特征的新型冠状病毒病综合征的干预措施并确定其优先顺序。将在专家共识研讨会上利用累积的证据提出建议。将与患者和卫生服务提供者共同制作一个虚拟的支持性干预措施，以供将来评估。有长期COVID生活经验的个人将通过患者和公众参与小组参与整个计划。从西米德兰兹郡的索利赫尔研究伦理委员会获得伦理批准（21/WM/0203）。研究结果将在国际会议上，在同行评审的期刊上，向长期COVID患者支持团体和政策制定者展示。1567490.
Individuals with COVID-19 frequently experience symptoms and impaired quality of life beyond 4–12 weeks, commonly referred to as Long COVID. Whether Long COVID is one or several distinct syndromes is unknown. Establishing the evidence base for appropriate therapies is needed. We aim to evaluate the symptom burden and underlying pathophysiology of Long COVID syndromes in non-hospitalised individuals and evaluate potential therapies. A cohort of 4000 non-hospitalised individuals with a past COVID-19 diagnosis and 1000 matched controls will be selected from anonymised primary care records from the Clinical Practice Research Datalink, and invited by their general practitioners to participate on a digital platform (Atom5). Individuals will report symptoms, quality of life, work capability and patient-reported outcome measures. Data will be collected monthly for 1 year. Statistical clustering methods will be used to identify distinct Long COVID-19 symptom clusters. Individuals from the four most prevalent clusters and two control groups will be invited to participate in the BioWear substudy which will further phenotype Long COVID symptom clusters by measurement of immunological parameters and actigraphy. We will review existing evidence on interventions for postviral syndromes and Long COVID to map and prioritise interventions for each newly characterised Long COVID syndrome. Recommendations will be made using the cumulative evidence in an expert consensus workshop. A virtual supportive intervention will be coproduced with patients and health service providers for future evaluation. Individuals with lived experience of Long COVID will be involved throughout this programme through a patient and public involvement group. Ethical approval was obtained from the Solihull Research Ethics Committee, West Midlands (21/WM/0203). Research findings will be presented at international conferences, in peer-reviewed journals, to Long COVID patient support groups and to policymakers. 1567490.
登录
查看更多内容
影响因子：
7.8
作者：
Nehme J;Borghesan M;Mackedenski S;Bird TG;Demaria M
通讯作者：
Demaria M
影响因子：
13.6
作者：
Gokhale KM;Chandan JS;Toulis K;Gkoutos G;Tino P;Nirantharakumar K
通讯作者：
Nirantharakumar K
影响因子：
17.3
作者：
Aiyegbusi OL;Hughes SE;Turner G;Rivera SC;McMullan C;Chandan JS;Haroon S;Price G;Davies EH;Nirantharakumar K;Sapey E;Calvert MJ;TLC Study Group
通讯作者：
TLC Study Group
影响因子：
82.9
作者：
Brodin, Petter
通讯作者：
Brodin, Petter
影响因子：
8.9
作者：
Jo C
通讯作者：
Jo C